CATRIDECACOG (Novothirteen ®)

Clinical Indication

Long term prophylaxis of bleeding in patients with congenital factor XIII A-subunit deficiency and bleeding episodes during regular prophylaxis.

Date of classification

September 2022


Not yet reviewed drugs with no traffic light recommendation so not yet approved for use in LLR.

  • New medicines, devices, appliances.
  • New indication of existing medicine.
  • New NICE TA which has not been reviewed.
  • Not been requested for review by either TAS/LPT MMC.